IL23A and psoriasis: Previously, in a phase II study in patients with recalcitrant psoriasis, treatment with apremilast 20 mg BID led to significant decreases in proinflammatory gene expression in the lesional skin, including IL-12/IL-23p40, IL-17A, and IL-23p19 [9].